Neuropathic PainNCT07650864
The Effect of Foot Massage With a Massage Roller on Chemotherapy-Related Neuropathic Pain
A study testing Roller Massage and Ice therapy in people with Neuropathic Pain and Chemotherapy Induced Pain Neuropathy, run by Ataturk University at 1 site in Turkey (Türkiye).
Trial summary
Chemotherapy-related neuropathic pain is experienced by 30-40% of cancer patients. This pain significantly reduces the quality of life and overall well-being of patients battling cancer. Studies widely acknowledge that standardizing neuropathic pain assessment leads to improved patient outcomes. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Neuropathic Pain, Chemotherapy Induced Pain Neuropathy
- What is being tested?
- Roller Massage and Ice therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Feb 2026to 30 Jul 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age ≥18, (2) receiving neurotoxic chemotherapy regimens including Taxanes (Paclitaxel/Docetaxel), Platinum (Carboplatin/Cisplatin), or a combination of both, (3) Having completed at least three cycles of chemotherapy, (4) scoring ≥ 12 on the S-LANSS scale, and ≥ 4 on the VAS, (5) being conscious, cooperative, and able to communicate in Turkish (6) volunteering to participate and providing written informed consent.
Who cannot join
- peripheral neuropathy pre-dating the chemotherapy (e.g., diabetic, alcoholic, or nutritional neuropathy) (2) receiving non-taxane/non-platinum regimens or Oxaliplatin-based chemotherapy, (3) active skin infections, open wounds, or severe scar tissue on the feet, (4) history of deep vein thrombosis or active bone/spine metastases in the lower extremities, (5) comorbidities affecting the sensory function of the nervous system.
Trial locations and contacts
1 site in 1 country.
About this study
Chemotherapy-related neuropathic pain is experienced by 30-40% of cancer patients. This pain significantly reduces the quality of life and overall well-being of patients battling cancer. Studies widely acknowledge that standardizing neuropathic pain assessment leads to improved patient outcomes. Our project, which we believe will add a different dimension to nursing care for cancer patients, aims to reduce chemotherapy-related neuropathic pain experienced by cancer patients through foot massage. The study population will consist of male and female cancer patients with chemotherapy-related neuropathic pain (VAS ≥ 4/10), over 18 years of age, who are actively undergoing treatment at the Medical Oncology Clinics of Atatürk University Research Hospital between February 1, 2026 and June 30, 2026, and who are not scheduled for surgical procedures during the research period. Accordingly, the minimum number of participants required for the study has been determined as 52. To reduce the risk of possible losses, withdrawals, or missing data during the research process, it is planned to include more participants than the calculated sample size. Within the scope of the research, the Neuropathic Pain Scale (S-LANSS) will be used to determine the presence of neuropathic pain in patients, and the VAS will be used to determine the severity of the pain. After the pre-test is completed, the control group will continue with routine treatment and care in the clinic. The intervention group will receive routine treatment and care, as well as foot massage using a foot massage roller for a total of 30 minutes twice a day. This intervention in the intervention group is planned to continue for 3 weeks. During this period, no other treatment will be applied to patients for neuropathic pain. The fact that only 3 small-scale studies, including one case report, were found in the literature review on this subject, the multidisciplinary collaboration in planning this study, and the expectation that it will offer practical solutions for chemotherapy-related neuropathic pain highlight the originality of the study. It is expected that the results obtained will provide evidence-based contributions to nursing care, support holistic approaches to improving patient comfort, and develop a viable intervention model for healthcare professionals.
- Being tested
- Roller Massage, Ice therapy
- Medical subject headings
- Neuralgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Roller MassageOther
intervention group
Ice therapyOther
control group
| Study group | Role | What they receive |
|---|---|---|
| wooden massage roller | Experimental | Not described Receives: Other: Roller Massage |
| ıce therapy | Active comparator | Not described Receives: Other: Ice therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analog Scale- Pain score
The Visual Analogue Scale (VAS), developed by Price et al. (1983), was utilized to assess and monitor pain intensity; it is a simple, repeatable, and widely used subjective method for rapid pain assessment [24]. In this method, participants marke their perceived pain on a 10 cm ruler, where 0 represent "no pain", and 10 represent 'the most severe or imaginable pain". In this study, pain intensity was categorized as 4 for "mild pain", 5-6 for "moderate pain", and 7-10 for "severe pain".
Measured: 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jun 2026
- Study start1 Feb 2026
- Primary completion30 Jun 2026
- Study completion30 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuropathic PainStudies of the same condition, open and under way.
- More trials run by Ataturk UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ataturk University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yasemin Ciraci Yasar, Ataturk University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07650864
- Sponsor's protocol ID
- TSA-2025-16152
- Status last verified
- Jun 2026
- First submitted
- 11 Jun 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Foot Massage With a Massage Roller on Chemotherapy-Related Neuropathic Pain
- ClinicalTrials.gov ID
- NCT07650864
- Acronym / sponsor ID
- TSA-2025-16152
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Ataturk UniversityUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jul 2026 (actual)
- First posted
- 16 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chemotherapy-related neuropathic pain is experienced by 30-40% of cancer patients. This pain significantly reduces the quality of life and overall well-being of patients battling cancer. Studies widely acknowledge that standardizing neuropathic pain assessment leads to improved patient outcomes. Our project, which we believe will add a different dimension to nursing care for cancer patients, aims to reduce chemotherapy-related neuropathic pain experienced by cancer patients through foot massage. The study population will consist of male and female cancer patients with chemotherapy-related neuropathic pain (VAS ≥ 4/10), over 18 years of age, who are actively undergoing treatment at the Medical Oncology Clinics of Atatürk University Research Hospital between February 1, 2026 and June 30, 2026, and who are not scheduled for surgical procedures during the research period. Accordingly, the minimum number of participants required for the study has been determined as 52. To reduce the risk of possible losses, withdrawals, or missing data during the research process, it is planned to include more participants than the calculated sample size. Within the scope of the research, the Neuropathic Pain Scale (S-LANSS) will be used to determine the presence of neuropathic pain in patients, and the VAS will be used to determine the severity of the pain. After the pre-test is completed, the control group will continue with routine treatment and care in the clinic. The intervention group will receive routine treatment and care, as well as foot massage using a foot massage roller for a total of 30 minutes twice a day. This intervention in the intervention group is planned to continue for 3 weeks. During this period, no other treatment will be applied to patients for neuropathic pain. The fact that only 3 small-scale studies, including one case report, were found in the literature review on this subject, the multidisciplinary collaboration in planning this study, and the expectation that it will offer practical solutions for chemotherapy-related neuropathic pain highlight the originality of the study. It is expected that the results obtained will provide evidence-based contributions to nursing care, support holistic approaches to improving patient comfort, and develop a viable intervention model for healthcare professionals.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| wooden massage roller | Experimental | Other: Roller Massage |
| ıce therapy | Active comparator | Other: Ice therapy |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- age ≥18, (2) receiving neurotoxic chemotherapy regimens including Taxanes (Paclitaxel/Docetaxel), Platinum (Carboplatin/Cisplatin), or a combination of both, (3) Having completed at least three cycles of chemotherapy, (4) scoring ≥ 12 on the S-LANSS scale, and ≥ 4 on the VAS, (5) being conscious, cooperative, and able to communicate in Turkish (6) volunteering to participate and providing written informed consent.
Key exclusion criteria (1 listed)
- peripheral neuropathy pre-dating the chemotherapy (e.g., diabetic, alcoholic, or nutritional neuropathy) (2) receiving non-taxane/non-platinum regimens or Oxaliplatin-based chemotherapy, (3) active skin infections, open wounds, or severe scar tissue on the feet, (4) history of deep vein thrombosis or active bone/spine metastases in the lower extremities, (5) comorbidities affecting the sensory function of the nervous system.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Roller Massageintervention group | Other | wooden massage roller |
| Ice therapycontrol group | Other | ıce therapy |
Primary outcome
Visual Analog Scale- Pain score
Time frame: 3 weeks
The Visual Analogue Scale (VAS), developed by Price et al. (1983), was utilized to assess and monitor pain intensity; it is a simple, repeatable, and widely used subjective method for rapid pain assessment [24]. In this method, participants marke their perceived pain on a 10 cm ruler, where 0 represent "no pain", and 10 represent 'the most severe or imaginable pain". In this study, pain intensity was categorized as 4 for "mild pain", 5-6 for "moderate pain", and 7-10 for "severe pain".
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Neuropathic Pain
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
RecruitingPhase 2
Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study
Cancer Pain, Orofacial Pain
RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Osteoarthritis, Knee, Diabetic Neuropathic Pain
RecruitingObservational study
Trigeminal Neuralgia Electrophysiology
Trigeminal Neuralgia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Roller Massage and Ice therapy in people with Neuropathic Pain and Chemotherapy Induced Pain Neuropathy, run by Ataturk University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analog Scale- Pain score (time frame: 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.